| Therapeutic potential for targeting autophagy in ER+ breast cancer RM Finnegan, AM Elshazly, PV Schoenlein, DA Gewirtz Cancers 14 (17), 4289, 2022 | 18 | 2022 |
| The cytoprotective, cytotoxic and nonprotective functional forms of autophagy induced by microtubule poisons in tumor cells—Implications for autophagy modulation as a … J Xu, AM Elshazly, DA Gewirtz Biomedicines 10 (7), 1632, 2022 | 18 | 2022 |
| The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant+ Palbociclib and suppresses proliferative recovery in ER-positive breast cancer RM Finnegan, AM Elshazly, NH Patel, L Tyutyunyk-Massey, TH Tran, ... Frontiers in Oncology 12, 966441, 2023 | 15 | 2023 |
| An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer AM Elshazly, DA Gewirtz Cancer Drug Resistance 5 (2), 472, 2022 | 15 | 2022 |
| Is autophagy induction by PARP inhibitors a target for therapeutic benefit? AM Elshazly, TVV Nguyen, DA Gewirtz Oncology research 30 (1), 1, 2022 | 13 | 2022 |
| Topoisomerase I poisons-induced autophagy: Cytoprotective, Cytotoxic or Non-protective AM Elshazly, PA Wright, J Xu, DA Gewirtz Autophagy reports 2 (1), 1-16, 2023 | 11 | 2023 |
| Senolytic therapy: A potential approach for the elimination of oncogene-induced senescent HPV-positive cells T Saleh, AI Khasawneh, N Himsawi, J Abu-Raideh, V Ejeilat, AM Elshazly, ... International Journal of Molecular Sciences 23 (24), 15512, 2022 | 11 | 2022 |
| Introduction to Mediterranean fruits bio-wastes: chemistry, functionality and techno-applications DM Elimam, MF Ramadan, AM Elshazly, MA Farag Mediterranean Fruits Bio-wastes: Chemistry, Functionality and Technological …, 2022 | 10 | 2022 |
| Is autophagy inhibition in combination with temozolomide a therapeutically viable strategy? AM Elshazly, DA Gewirtz Cells 12 (4), 535, 2023 | 9 | 2023 |
| Cytoprotective, cytotoxic and cytostatic roles of autophagy in response to BET inhibitors AM Elshazly, DA Gewirtz International Journal of Molecular Sciences 24 (16), 12669, 2023 | 6 | 2023 |
| Making the case for autophagy inhibition as a therapeutic strategy in combination with androgen-targeted therapies in prostate cancer AM Elshazly, DA Gewirtz Cancers 15 (20), 5029, 2023 | 5 | 2023 |
| BRD4 inhibition as a strategy to prolong the response to standard of care in estrogen receptor-positive breast cancer AM Elshazly, MM Sinanian, V Neely, E Chakraborty, MA Alshehri, ... Cancers 15 (16), 4066, 2023 | 4 | 2023 |
| The Cytoprotective Role of Autophagy in Response to BRAF-Targeted Therapies AM Elshazly, DA Gewirtz International Journal of Molecular Sciences 24 (19), 14774, 2023 | 3 | 2023 |
| Dantrolene and coenzyme Q10 as a suggested combination therapy to statin-induced myopathy in high fat diet rats: A possible interference with ROS/TGF-β/Smad4 signaling pathway S Zakaria, AM Elshazly, R Alaa, S Elsebaey Toxicology and Applied Pharmacology 485, 116900, 2024 | 2 | 2024 |
| Autophagy and senescence facilitate the development of antiestrogen resistance in ER positive breast cancer MK McGrath, A Abolhassani, L Guy, AM Elshazly, JT Barrett, NF Mivechi, ... Frontiers in Endocrinology 15, 1298423, 2024 | 2 | 2024 |
| Overview of the Molecular Modalities and Signaling Pathways Intersecting with β-Amyloid and Tau Protein in Alzheimer’s Disease AM Elshazly, MM Sinanian, DM Elimam, S Zakaria Neuroglia 4 (3), 191-208, 2023 | 2 | 2023 |
| The Cytoprotective and Cytotoxic Functions of Autophagy in Response to mTOR Inhibitors AM Elshazly, AA Elzahed, DA Gewirtz Frontiers in Bioscience-Landmark 29 (6), 231, 2024 | 1 | 2024 |
| Evidence for cytoprotective autophagy in response to HER2-targeted monoclonal antibodies AM Elshazly, AA Elzahed, DA Gewirtz Journal of Pharmacology and Experimental Therapeutics, 2024 | 1 | 2024 |
| Focus: Cell Fate: OMA1 and YME1L as a Diagnostic Panel in Hepatocellular Carcinoma SA Abass, NM Abdel-Hamid, AM Elshazly, W Abdo, S Zakaria The Yale Journal of Biology and Medicine 96 (4), 443, 2023 | 1 | 2023 |
| Is Autophagy Targeting a Valid Adjuvant Strategy in Conjunction with Tyrosine Kinase Inhibitors? AM Elshazly, J Xu, N Melhem, A Abdulnaby, AA Elzahed, T Saleh, ... Cancers 16 (17), 2989, 2024 | | 2024 |
Diaaeldin Mohamed Abdelkawi ElimamPhD - SMCB, University of Leeds/ Assistant lecturer of pharmacognosy - Kafrelsheikh University在 pharm.kfs.edu.eg 的电子邮件经过验证
